These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of peplomycin plus carbazilquinone and mitomycin on non-small cell carcinoma of the lung.
    Author: Saijo N, Shimizu E, Eguchi K, Shinkai T, Tominaga K, Shibuya M, Shimabukuro Z, Niitani H, Hoshi A.
    Journal: Cancer Treat Rep; 1983 Apr; 67(4):385-7. PubMed ID: 6189601.
    Abstract:
    The effects of two chemotherapeutic regimens, peplomycin (PLM) plus carbazilquinone and PLM plus mitomycin, on non-small cell carcinoma of the lung were evaluated by a randomized controlled trial. Seven partial responses were observed in 53 evaluable patients, for an overall response rate of 13.2%. There was no difference in response rate or in median survival time between PLM plus carbazilquinone (11.5% and 32 weeks) and PLM plus mitomycin (14.8% and 25 weeks). Seven patients developed interstitial pneumonitis, and four died of pulmonary fibrosis. It was concluded that the chemotherapeutic regimens that include PLM are only marginally effective against non-small cell carcinoma of the lung, with relatively frequent pulmonary fibrosis.
    [Abstract] [Full Text] [Related] [New Search]